| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18251 R76599 |
Suarez (Controls unexposed, discontinuers), 2022 | Any Specific Neurodevelopmental Disorder (ASD, ADHD, language disorder, learning disorders, intellectual disability, Developmental Coordination Disorder) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.14 [1.00;1.29] | 2,323/26,595 493/7,773 | 2,816 | 26,595 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18252 R76607 |
Suarez (Controls unexposed, general pop), 2022 | Any Specific Neurodevelopmental Disorder (ASD, ADHD, language disorder, learning disorders, intellectual disability, Developmental Coordination Disorder) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
1.20 [1.15;1.26] excluded (control group) |
2,328/26,659 134,536/2,984,014 | 136,864 | 26,659 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10193 R37361 |
Heikkinen, 2003 | Abnormal neurologic development - Modified Gesell developmental schedules (at 1 year) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 0.90 [0.02;50.25] C | 0/11 0/10 | 0 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 1.14 [1.00;1.29] | 2,816 | 26,606 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, discontinuers;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 18252